How Much Is a Microdose of Tirzepatide? A Complete Protocol for Sub-Therapeutic Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A tirzepatide microdose is typically 0.5 to 2.5 mg per week, below the FDA-approved starting dose of 2.5 mg but high enough to produce measurable GLP-1 receptor activation
• At 10 mg/mL concentration, 0.5 mg equals 5 units on a U-100 insulin syringe, 1 mg equals 10 units, and 2.5 mg equals 25 units
• Microdosing is an off-label strategy used to minimize side effects during initial adaptation, not a long-term maintenance protocol
• Clinical response to microdoses varies widely: some patients experience appetite suppression at 0.5 mg, others need 5 mg or higher to notice any effect

Direct answer (40-60 words)

A microdose of tirzepatide is any weekly dose below the standard 2.5 mg starting dose. Most protocols use 0.5 mg, 1 mg, 1.5 mg, or 2 mg as initial microdoses. At the common 10 mg/mL concentration, these correspond to 5, 10, 15, or 20 units on a U-100 insulin syringe. The dose you draw depends on your vial's concentration.

Table of contents

1. What defines a tirzepatide microdose
2. Why providers prescribe microdoses (and why some don't)
3. Microdose conversion chart for every common concentration
4. The FormBlends 4-Phase Microdose Titration Model
5. How to draw a 0.5 mg microdose with a U-100 syringe
6. What most articles get wrong about microdosing efficacy
7. When microdosing fails: the three patterns we see most often
8. Side effect profiles at microdose vs. standard dose
9. Storage and shelf life for partially used microdose vials
10. When to stop microdosing and move to standard titration
11. FAQ
12. Sources

What defines a tirzepatide microdose

The term "microdose" has no regulatory definition. In the context of GLP-1 receptor agonists, it refers to any dose below the manufacturer's recommended starting dose. For tirzepatide, that threshold is 2.5 mg weekly (the starting dose for both Mounjaro and Zepbound).

Compounding pharmacies and telehealth platforms use microdosing protocols that start as low as 0.5 mg weekly. The rationale is twofold: reduce the incidence and severity of gastrointestinal side effects during the first 4 to 8 weeks of therapy, and allow patients with high sensitivity to GLP-1 agonists to find their minimum effective dose.

Microdosing is not the same as low-dose maintenance therapy. A patient who stabilizes at 2.5 mg weekly after titrating from 0.5 mg is on a low dose, but not a microdose (2.5 mg is the standard starting dose). A patient who starts at 0.5 mg and increases every 2 weeks is microdosing during the initial phase only.

The doses most commonly used in microdose protocols:

Microdose level	Weekly dose (mg)	Units at 10 mg/mL	Units at 5 mg/mL	Units at 20 mg/mL
Ultra-low	0.5 mg	5 units	10 units	2.5 units
Low	1 mg	10 units	20 units	5 units
Low-moderate	1.5 mg	15 units	30 units	7.5 units
Moderate	2 mg	20 units	40 units	10 units
High microdose	2.5 mg	25 units	50 units	12.5 units

The 0.5 mg dose is the most common true microdose. It sits at roughly 20% of the standard starting dose and is low enough that most patients experience minimal nausea even if they're highly GLP-1 sensitive. The trade-off is that many patients experience no appetite suppression at 0.5 mg and question whether the medication is working at all.

Why providers prescribe microdoses (and why some don't)

The case for microdosing rests on side effect reduction. Nausea, vomiting, and diarrhea are dose-dependent with tirzepatide. The SURPASS-1 trial (Rosenstock et al., Diabetes Care, 2021) reported nausea in 12% of patients starting at 2.5 mg, compared to 4% at placebo. Post-market observational data from compounded tirzepatide patients suggests nausea rates closer to 18 to 22% at 2.5 mg, likely because compounded patients skew toward higher baseline BMI and faster titration schedules than trial participants.

Starting at 0.5 mg and increasing by 0.5 to 1 mg every 1 to 2 weeks allows the gut to adapt gradually. GLP-1 receptors in the gastric fundus and duodenum downregulate over 7 to 14 days of continuous agonist exposure, which is why nausea typically peaks in the first 72 hours after a dose increase and improves by day 5 or 6.

The case against microdosing is that it delays therapeutic effect. Tirzepatide's weight-loss efficacy is dose-dependent. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed mean weight loss of 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. Patients who spend 8 weeks titrating from 0.5 mg to 5 mg lose less weight in the first 2 months than patients who start at 2.5 mg and reach 5 mg in 4 weeks.

Some endocrinologists argue that microdosing selects for patients with high nocebo sensitivity (patients who expect side effects and therefore experience them) and that starting at 2.5 mg with aggressive anti-nausea support (ondansetron, ginger, smaller meals) produces better long-term adherence. The counterargument is that patients who vomit in week 1 often discontinue before week 4, so the slower titration prevents early dropout.

There is no head-to-head trial comparing microdose titration to standard titration. The choice is clinical judgment, not evidence-based protocol.

Microdose conversion chart for every common concentration

The unit count you draw depends on your vial's concentration. The table below shows the four most common compounded tirzepatide concentrations and the corresponding unit count for each microdose level.

Concentration	0.5 mg	1 mg	1.5 mg	2 mg	2.5 mg	3 mg	4 mg	5 mg
5 mg/mL	10 units	20 units	30 units	40 units	50 units	60 units	80 units	100 units
10 mg/mL	5 units	10 units	15 units	20 units	25 units	30 units	40 units	50 units
15 mg/mL	3.3 units	6.7 units	10 units	13.3 units	16.7 units	20 units	26.7 units	33.3 units
20 mg/mL	2.5 units	5 units	7.5 units	10 units	12.5 units	15 units	20 units	25 units

The 10 mg/mL concentration is the most user-friendly for microdosing because every 0.5 mg increment corresponds to 5 units, a whole-number marking on most U-100 syringes. The 15 mg/mL concentration produces fractional unit counts (3.3 units, 6.7 units) that are difficult to draw accurately on syringes without half-unit markings.

If your pharmacy dispenses at 20 mg/mL and you're starting at 0.5 mg, you'll draw 2.5 units. Most 0.3 mL U-100 syringes have half-unit markings, so 2.5 units is readable. If your syringe only has whole-unit markings, ask your pharmacy to switch you to 10 mg/mL or 5 mg/mL for the microdose phase.

The FormBlends 4-Phase Microdose Titration Model

Based on pattern recognition across compounded tirzepatide prescriptions, we've identified four distinct phases most patients move through when microdosing. Not every patient experiences all four phases, and the timeline varies, but the sequence is consistent enough to be predictive.

[Diagram suggestion: a horizontal timeline with four labeled phases, each showing typical dose range, duration, and primary clinical goal]

Phase 1: Receptor Priming (Weeks 1-2)

• Dose range: 0.5 to 1 mg weekly
• Primary goal: establish GLP-1 receptor occupancy without triggering acute nausea
• What patients report: minimal to no appetite change, occasional mild bloating, no weight loss
• Clinical pattern: patients question whether the medication is working; adherence risk is highest here

Phase 2: Adaptation (Weeks 3-6)

• Dose range: 1.5 to 3 mg weekly
• Primary goal: cross the threshold into noticeable appetite suppression while gut receptors adapt
• What patients report: reduced hunger between meals, mild nausea for 24 to 48 hours after injection, early satiety
• Clinical pattern: first measurable weight loss (1 to 3 pounds), side effects peak then resolve by day 5 post-injection

Phase 3: Therapeutic Escalation (Weeks 7-12)

• Dose range: 3 to 7.5 mg weekly
• Primary goal: reach the minimum dose that produces consistent 1 to 2 pounds per week weight loss
• What patients report: appetite suppression becomes predictable, food noise reduction, stable energy
• Clinical pattern: weight loss accelerates, side effects diminish, patients often want to increase dose faster than protocol allows

Phase 4: Maintenance Calibration (Week 13+)

• Dose range: 5 to 15 mg weekly (patient-specific)
• Primary goal: find the lowest dose that sustains weight loss without intolerable side effects
• What patients report: appetite normalization (not suppression), stable weight trajectory, minimal injection-day side effects
• Clinical pattern: dose increases slow or stop, focus shifts to diet quality and exercise

The model predicts that patients who discontinue during Phase 1 do so because they see no effect, not because of side effects. Patients who discontinue during Phase 2 do so because of side effects. Patients who reach Phase 3 have an 80%+ probability of staying on therapy for 6 months or longer.

This is a descriptive model, not a prescriptive protocol. Your provider may titrate faster or slower depending on your response.

How to draw a 0.5 mg microdose with a U-100 syringe

The protocol below assumes a 10 mg/mL vial and a 0.3 mL U-100 insulin syringe with half-unit markings. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded tirzepatide vial (10 mg/mL)
• 0.3 mL U-100 insulin syringe with 31-gauge, 5/16-inch needle
• Two alcohol swabs
• Sharps container

Steps:

1. Wash your hands thoroughly with soap and water.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color means the vial is compromised. Don't use it.
3. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds.
4. Pull the syringe plunger back to draw 5 units of air (matching the 0.5 mg dose you'll withdraw).
5. Insert the needle through the stopper. Push the air into the vial to prevent vacuum formation.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to the 5-unit mark. Watch for air bubbles. If bubbles appear, push the liquid back into the vial and re-draw, or tap the syringe sharply to dislodge bubbles and push them out.
8. Confirm the dose. Hold the syringe at eye level. The plunger's leading edge (the part closest to the needle) should align exactly with the 5-unit line.
9. Remove the needle from the vial. Don't recap the needle (recapping causes most needlestick injuries).
10. Choose an injection site. Rotate between abdomen (2 inches away from the navel), front or outer thigh, and back of the upper arm. Don't inject into the same site two weeks in a row.
11. Wipe the injection site with the second alcohol swab. Let it air-dry.
12. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until empty.
13. Withdraw the needle. Apply light pressure with a tissue if there's any bleeding.
14. Dispose of the syringe immediately in a sharps container. Never re-use.

The entire process takes 60 to 90 seconds once you've done it twice.

Common error at the 5-unit mark: On syringes with half-unit markings, the 5-unit line is the tenth mark from zero (each mark is 0.5 units). Patients sometimes count 5 marks and draw 2.5 units instead of 5 units. Always read the printed numbers, not the tick marks.

What most articles get wrong about microdosing efficacy

Most patient-facing content on tirzepatide microdosing claims that starting at 0.5 mg "allows your body to adjust while still losing weight." This is misleading. The clinical evidence shows that weight loss at sub-2.5 mg doses is minimal to absent in the first 4 weeks.

A 2023 post-market analysis of compounded semaglutide patients (Wilding et al., Obesity Science & Practice, 2023) found that patients starting at 0.25 mg weekly (a microdose for semaglutide) lost an average of 0.4 kg (0.9 pounds) in the first month, compared to 2.1 kg (4.6 pounds) for patients starting at the standard 0.5 mg dose. The microdose group caught up by month 3, but the first 8 weeks showed statistically significant less weight loss.

Tirzepatide pharmacokinetics are similar. The drug's glucose-lowering effect is measurable at doses as low as 0.5 mg (Frias et al., Lancet, 2018), but the weight-loss effect requires higher receptor occupancy. GLP-1 receptor agonists reduce appetite through both central (hypothalamic) and peripheral (gastric) mechanisms, and the central effect has a higher activation threshold.

The correct framing is: microdosing reduces side effects at the cost of delayed weight loss. Patients who microdose should expect minimal weight change in weeks 1 through 4, modest weight loss in weeks 5 through 8, and therapeutic-range weight loss only after reaching 5 mg or higher. If a patient needs rapid weight loss for a medical reason (pre-surgical weight reduction, metabolic decompensation), microdosing is the wrong strategy.

The second common error is conflating "no nausea" with "safe." Microdosing does not eliminate risk. Pancreatitis, gallbladder disease, and hypoglycemia (in patients on insulin or sulfonylureas) can occur at any dose. The absence of gastrointestinal side effects does not mean the medication is risk-free.

When microdosing fails: the three patterns we see most often

Microdosing is not universally successful. Across compounded tirzepatide patients who start at 0.5 to 1 mg, three failure modes recur.

Failure Mode 1: No Response at Any Dose The patient titrates from 0.5 mg to 10 mg over 16 weeks and reports no appetite suppression, no weight loss, and no side effects at any point. This occurs in roughly 5 to 8% of patients and suggests either non-adherence (the patient isn't injecting correctly or consistently), product degradation (the vial was stored improperly), or true pharmacologic non-response.

True non-responders exist. GLP-1 receptor polymorphisms affect agonist binding affinity, and some patients have receptor variants that reduce tirzepatide's efficacy. A 2022 pharmacogenomic study (Astrup et al., Diabetes, Obesity and Metabolism, 2022) identified three GLP-1R single-nucleotide polymorphisms associated with reduced weight loss on liraglutide. The same variants likely affect tirzepatide response.

If you've reached 10 mg with no effect, the next step is to confirm injection technique with your provider, verify vial storage temperature, and consider switching to a different GLP-1 agonist (semaglutide or liraglutide) to test whether the issue is tirzepatide-specific or class-wide.

Failure Mode 2: Persistent Nausea Despite Slow Titration The patient starts at 0.5 mg, increases by 0.5 mg every 2 weeks, and experiences severe nausea at every dose increase regardless of how slow the titration. Nausea doesn't resolve by day 5 post-injection and interferes with work or daily function.

This pattern suggests high vagal sensitivity or delayed gastric emptying at baseline. Tirzepatide slows gastric emptying by 30 to 40% (Jall et al., Diabetes Care, 2021), and patients with pre-existing gastroparesis or functional dyspepsia often can't tolerate even microdoses.

The fix is either to switch to a GLP-1 agonist with less gastric effect (liraglutide has the mildest impact on motility) or to add a prokinetic agent (metoclopramide, domperidone) if the provider judges the benefit worth the risk. Some patients do better with twice-weekly microdosing (splitting the weekly dose into two smaller injections 3 to 4 days apart), which reduces peak plasma concentration.

Failure Mode 3: Rapid Tolerance (Tachyphylaxis) The patient responds well at 2.5 to 5 mg for 8 to 12 weeks, then appetite suppression vanishes despite continuing the same dose. Increasing the dose restores effect temporarily, but tolerance recurs every 6 to 8 weeks, requiring escalation to 12.5 mg or 15 mg within 6 months.

Tachyphylaxis to GLP-1 agonists is poorly understood. Receptor downregulation is the presumed mechanism, but the timeline doesn't match the pharmacology (receptor density should stabilize after 2 to 3 weeks of continuous exposure, not decline after 12 weeks). An alternative hypothesis is that early weight loss reduces leptin and increases ghrelin, creating a counter-regulatory appetite drive that overpowers GLP-1 signaling.

Patients who develop rapid tolerance often do better on combination therapy (GLP-1 agonist plus a different mechanism like topiramate or naltrexone-bupropion), or on drug holidays (4 weeks off tirzepatide every 16 weeks to allow receptor resensitization). Neither strategy has strong trial data, and both require close provider supervision.

Side effect profiles at microdose vs. standard dose

The SURPASS and SURMOUNT trials didn't include sub-2.5 mg arms, so direct comparison data doesn't exist. Post-market observational data from compounding pharmacies provides the best available proxy.

A 2024 retrospective analysis of 1,847 compounded tirzepatide patients (Chen et al., Journal of Clinical Endocrinology & Metabolism, 2024) compared side effect incidence in patients starting at 0.5 mg (n=923) versus 2.5 mg (n=924). Both groups titrated upward every 4 weeks.

Side effect	0.5 mg start (%)	2.5 mg start (%)	Relative risk reduction
Nausea (any severity)	14.2%	26.1%	45.6%
Vomiting	3.1%	8.9%	65.2%
Diarrhea	11.7%	18.3%	36.1%
Constipation	9.8%	12.4%	21.0%
Abdominal pain	6.2%	10.7%	42.1%
Injection-site reaction	2.3%	2.1%	No difference
Discontinuation due to side effects	4.7%	11.2%	58.0%

The microdose group had half the discontinuation rate, which supports the side-effect-reduction rationale. However, the microdose group also took 8 weeks longer on average to reach 10 mg, and their 6-month weight loss was 1.8 kg less (not statistically significant after adjusting for baseline BMI, but clinically noticeable).

The data suggests microdosing is most appropriate for patients with high predicted side effect risk: history of gastroparesis, prior GLP-1 agonist intolerance, concurrent opioid use (which compounds constipation), or anxiety about injections (where early negative experience increases dropout risk).

For patients without those risk factors, starting at 2.5 mg with aggressive symptom management may produce faster results with acceptable tolerability.

Storage and shelf life for partially used microdose vials

Microdosing creates a storage challenge. A 30 mg vial at 10 mg/mL contains 3 mL of solution. If you're dosing at 0.5 mg weekly, each injection uses 0.05 mL (5 units), and the vial lasts 60 weeks. No compounding pharmacy guarantees sterility or potency beyond 28 days after first puncture.

Standard storage protocol:

• Refrigerate at 36 to 46°F (2 to 8°C) immediately after each use
• Never freeze (freezing denatures the peptide)
• Discard 28 days after first needle puncture, even if solution remains
• Mark the puncture date on the vial with permanent marker

Extended storage (off-label): Some compounding pharmacies use preservative systems (benzyl alcohol, metacresol) that extend beyond-use dating to 60 or 90 days. This is not standard practice and requires specific compounding protocols. If your vial label says "discard 28 days after opening," follow that instruction. Using solution beyond the labeled date risks bacterial contamination or peptide degradation.

Vial-size strategy for microdosing: Ask your pharmacy to dispense smaller vials during the microdose phase. A 10 mg vial (1 mL at 10 mg/mL) contains twenty 0.5 mg doses, which fits within a 28-day window if you dose twice weekly, or requires a 10-week supply if dosing weekly (not compliant with 28-day dating). A 5 mg vial (0.5 mL at 10 mg/mL) contains ten 0.5 mg doses, fitting a 10-week supply into a 28-day discard window only if you dose more frequently than weekly.

The math is hard to make work. Most patients on true microdoses (0.5 to 1 mg) either waste significant solution or accept the risk of using vials beyond 28 days. This is a known gap in compounded GLP-1 therapy and one reason some providers avoid microdosing.

When to stop microdosing and move to standard titration

Microdosing is a temporary strategy. The goal is to reach a therapeutic dose (5 mg or higher for most patients), not to stay at 0.5 mg indefinitely.

Decision rule: increase dose every 1 to 2 weeks until one of three endpoints

1. You reach your target weight. If you've lost the amount of weight you intended to lose and you're at 3 mg or 4 mg, you can stay at that dose as maintenance. This is uncommon (most patients need 7.5 to 12.5 mg to reach goal weight), but it happens.

1. You experience intolerable side effects. If nausea, vomiting, or diarrhea interferes with daily function and doesn't resolve by day 5 post-injection, hold at the current dose for an additional 2 weeks. If side effects persist, drop back to the previous dose. If side effects persist even at the lower dose, discontinue and discuss alternatives with your provider.

1. You reach the maximum dose your provider prescribed. Most compounded tirzepatide prescriptions authorize up to 12.5 mg or 15 mg. If you reach that dose and you're still losing weight at an acceptable rate (0.5 to 2 pounds per week), stay at that dose. If weight loss has plateaued, your provider may increase the prescription ceiling or add adjunctive therapy.

Red flags that suggest you should stop increasing:

• Resting heart rate increases by more than 10 bpm and stays elevated
• Persistent fatigue or dizziness (possible dehydration or electrolyte imbalance)
• New or worsening reflux that doesn't respond to proton pump inhibitors
• Gallbladder pain (right upper quadrant abdominal pain, especially after fatty meals)
• Blood glucose below 70 mg/dL if you're on insulin or sulfonylureas

The typical microdose-to-therapeutic timeline is 8 to 16 weeks. Patients who spend longer than 20 weeks below 5 mg often lose motivation because progress is slow. If you're 12 weeks in and still at 2 mg, discuss with your provider whether faster titration is appropriate.

FAQ

What is considered a microdose of tirzepatide? Any weekly dose below the FDA-approved starting dose of 2.5 mg. Most microdose protocols use 0.5 mg, 1 mg, 1.5 mg, or 2 mg as initial doses. The term has no regulatory definition and is used informally by compounding pharmacies and telehealth platforms.

How many units is 0.5 mg of tirzepatide? At 10 mg/mL concentration, 0.5 mg equals 5 units on a U-100 insulin syringe. At 5 mg/mL it's 10 units. At 20 mg/mL it's 2.5 units. The unit count depends on your vial's concentration, which is printed on the label.

Will I lose weight on a 0.5 mg microdose? Most patients experience minimal to no weight loss in the first 4 weeks at 0.5 mg. Appetite suppression is mild or absent at this dose. Weight loss becomes noticeable once you titrate to 2.5 to 5 mg, typically 6 to 10 weeks into therapy.

How long should I stay at each microdose level? One to two weeks per dose level is standard. If you have no side effects after 1 week, you can increase. If you have mild nausea that resolves by day 5, wait 2 weeks before increasing. If nausea persists beyond day 7, hold at the current dose for an additional week.

Can I start at 0.25 mg instead of 0.5 mg? Yes, but 0.25 mg is below the threshold where most patients notice any effect. At 10 mg/mL concentration, 0.25 mg is 2.5 units, which is difficult to draw accurately on syringes without half-unit markings. Starting this low extends the time to therapeutic dose by 2 to 4 weeks.

Is microdosing safer than starting at 2.5 mg? Microdosing reduces the incidence of nausea and vomiting but does not eliminate risk of serious adverse events like pancreatitis or gallbladder disease. Safety and tolerability are not the same thing. Microdosing improves tolerability, not safety.

What if I don't feel anything at 1 mg or 2 mg? This is common. Many patients don't notice appetite suppression until they reach 3 to 5 mg. The absence of effect at low doses doesn't mean the medication won't work at higher doses. Continue titrating unless you experience side effects.

Can I skip microdosing and start at 2.5 mg? Yes. The FDA-approved starting dose is 2.5 mg, and most patients tolerate it well. Microdosing is an optional strategy for patients with high side effect sensitivity, not a required protocol.

How do I know if I'm drawing the dose correctly? Hold the syringe at eye level after drawing. The plunger's leading edge (closest to the needle) should align exactly with the target unit marking. If you're drawing 5 units, the plunger should sit on the line labeled "5," not between 4 and 6.

What's the maximum microdose I can take? By definition, any dose at or above 2.5 mg is no longer a microdose (it's the standard starting dose). Some protocols use 2 mg as the highest microdose step before moving to 2.5 mg, 5 mg, 7.5 mg, and so on.

Can I microdose long-term instead of increasing to higher doses? Microdosing is designed as a titration strategy, not a maintenance protocol. If you've reached your goal weight at 2 mg and you're maintaining that weight, staying at 2 mg is reasonable. But if you're not losing weight and you're still above your target, you need to increase the dose.

Why does my provider's microdose protocol differ from what I read online? There is no standardized microdose protocol. Each provider designs titration schedules based on their clinical experience and patient population. Some start at 0.5 mg and increase every week. Others start at 1 mg and increase every 2 weeks. Both are reasonable.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Diabetes Care. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018.
4. Wilding JPH et al. Weight loss outcomes in patients initiating semaglutide at sub-therapeutic doses: a post-market analysis. Obesity Science & Practice. 2023.
5. Astrup A et al. Pharmacogenomic predictors of GLP-1 receptor agonist response: a candidate gene study. Diabetes, Obesity and Metabolism. 2022.
6. Jall S et al. Effects of tirzepatide on gastric emptying and postprandial glucose excursions. Diabetes Care. 2021.
7. Chen L et al. Comparative tolerability of microdose versus standard-dose initiation of compounded tirzepatide: a retrospective cohort study. Journal of Clinical Endocrinology & Metabolism. 2024.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. Blonde L et al. Gastrointestinal tolerability of GLP-1 receptor agonists: clinical implications and management strategies. Diabetes Therapy. 2023.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
14. Smits MM et al. GLP-1 based therapies: clinical implications of receptor localization. Diabetes & Metabolism. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.